Everything is done for a reason. There is enough data to narrow down commercial opportunities without simply going off and doing preclinicals on random things.
I would imagine that the thought process is as follows:
1. AML (Bisantrene+Decitabine) -> P2 results -> licensing.
2. Solid tumour (all comers) Bisantrene+Decitabine drug supply -> Investigator sponsor -> licensing.
3. Kyprolis+Bisantrene (CPACS) -> Drug supply -> investigator sponsor-> licensing
4. CPACS (Dox+Bisantrene) all comers - Amgen?
Everything is done for a reason. There is enough data to narrow...
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
